# Treating Heart Failure With hiPSC-CMs

> **NCT05223894** · PHASE1,PHASE2 · UNKNOWN · sponsor: **HELP Therapeutics Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Heart Failure

## Interventions

- **BIOLOGICAL:** hiPSC-CM therapy
- **OTHER:** Control

## Key facts

- **NCT ID:** NCT05223894
- **Lead sponsor:** HELP Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-30
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-11-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05223894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05223894, "Treating Heart Failure With hiPSC-CMs". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05223894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*